SCHEMBL6447772

SCHEMBL6447772

N#Cc1c(NC2CCCCC2)nc(N)nc1-c1ccco1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.68
ALDH1A1 P00352 4/20 0.68
HPGD P15428 4/20 0.68
GAA P10253 3/20 0.68
NPSR1 Q6W5P4 2/20 0.68
HSD17B10 Q99714 3/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
CASP1 P29466 2/20 0.59
MAPT P10636 1/20 0.59
TSHR P16473 1/20 0.59
ALOX12 P18054 1/20 0.59
ATM Q13315 1/20 0.59
ADORA1 P30542 9/20 0.55
ADORA2A P29274 7/20 0.55
ADORA2B P29275 5/20 0.55
ADORA3 P0DMS8 3/20 0.53
CHUK O15111 1/20 0.46
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23162573 0.99 KDM4E (0.66) KDM4EALDH1A1HPGDGAANPSR1
SCHEMBL6444870 0.85 KDM4E (0.51) KDM4EALDH1A1HPGDGAANPSR1
SCHEMBL23162598 0.84 ADORA1 (0.52) KDM4EALDH1A1HPGDGAANPSR1
SCHEMBL6442381 0.81 ADORA1 (0.58) ADORA1ADORA2AADORA2BCHUK
SCHEMBL6441851 0.79 ADORA2A (0.64) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL5046621 0.77 ADORA2A (0.55) KDM4EALDH1A1HPGDGAANPSR1
SCHEMBL6446015 0.77 ADORA2A (0.61) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL6446329 0.75 ALDH1A1 (0.52) KDM4EALDH1A1HPGDGAANPSR1
SCHEMBL6441202 0.75 ADORA2A (0.72) KDM4EALDH1A1HPGDGAAHSD17B10
SCHEMBL6441991 0.74 ADORA2A (0.57) KDM4EALDH1A1HPGDGAANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 KDM4E 3250/4885ALDH1A1 534/4885HPGD 915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.